Volume 38, Issue 3 1 pp. 742-747
Article

Indication for Liver Transplantation in Young Patients with Small Intestinal NETs Is Rare?

Olov Norlén

Olov Norlén

Department of Surgical Sciences, University Hospital, Uppsala University, 751 85 Uppsala, Sweden

Search for more papers by this author
Kosmas Daskalakis

Kosmas Daskalakis

Department of Surgical Sciences, University Hospital, Uppsala University, 751 85 Uppsala, Sweden

Search for more papers by this author
Kjell Öberg

Kjell Öberg

Department of Medical Sciences, University Hospital, Uppsala University, 751 85 Uppsala, Sweden

Search for more papers by this author
Göran Åkerström

Göran Åkerström

Department of Surgical Sciences, University Hospital, Uppsala University, 751 85 Uppsala, Sweden

Search for more papers by this author
Peter Stålberg

Peter Stålberg

Department of Surgical Sciences, University Hospital, Uppsala University, 751 85 Uppsala, Sweden

Search for more papers by this author
Per Hellman

Corresponding Author

Per Hellman

Department of Surgical Sciences, University Hospital, Uppsala University, 751 85 Uppsala, Sweden

[email protected]Search for more papers by this author
First published: 14 November 2013
Citations: 20

Abstract

Background

A majority of patients with small intestinal neuroendocrine tumors (SI-NETs) present with or develop liver metastases (LM). A number of treatments for LM are used clinically, including liver transplantation (LTx). Indications for LTx are under debate; young age (<65 years), absence of extrahepatic disease, resected primary tumor and limited extent of LM have been suggested as inclusion criteria for LTx with the aim to optimize outcome.

Materials and methods

From our series of 672 patients with SI-NET treated at the University Hospital in Uppsala between 1985 and 2012, we identified 78 patients according to the following criteria: <65 years of age, locoregional surgery (LRS) of the primary tumor and mesenteric metastases successfully performed, LM present but no extrahepatic disease. Baseline was chosen as the first date the following points were met: First visit to our center, LRS performed, LM present. The patients underwent treatment according to the standard clinical protocols at our center, and during this time period we did not perform or refer any SI-NET patients for LTx. Kaplan–Meier survival analyses were performed in three different groups based on hypothetical criteria for LTx.

Results

Five-year overall survival rates for patients <65 years (n = 78) and <55 years (n = 36) of age were 84 ± 8 and 92 ± 9 %, respectively. For patients fulfilling the Milan criteria (n = 33) the 5-year survival was 97 ± 6 %.

Conclusions

Most young patients (<65 years) with SI-NET and LM have a favorable survival with standardized multimodality treatment. Indeed, most survival figures reported after LTx of NET do not surpass these figures.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.